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Sulfur is both crucial to life and a potential threat to health. While colonic sulfur metabolism
mediated by eukaryotic cells is relatively well studied, much less is known about sulfur
metabolism within gastrointestinal microbes. Sulfated compounds in the colon are either
of inorganic (e.g., sulfates, sulfites) or organic (e.g., dietary amino acids and host mucins)
origin. The most extensively studied of the microbes involved in colonic sulfur metabolism
are the sulfate-reducing bacteria (SRB), which are common colonic inhabitants. Many
other microbial pathways are likely to shape colonic sulfur metabolism as well as the
composition and availability of sulfated compounds, and these interactions need to be
examined in more detail. Hydrogen sulfide is the sulfur derivative that has attracted the
most attention in the context of colonic health, and the extent to which it is detrimental
or beneficial remains in debate. Several lines of evidence point to SRB or exogenous
hydrogen sulfide as potential players in the etiology of intestinal disorders, inflammatory
bowel diseases (IBDs) and colorectal cancer in particular. Generation of hydrogen sulfide
via pathways other than dissimilatory sulfate reduction may be as, or more, important
than those involving the SRB. We suggest here that a novel axis of research is to
assess the effects of hydrogen sulfide in shaping colonic microbiome structure. Clearly,
in-depth characterization of the microbial pathways involved in colonic sulfur metabolism
is necessary for a better understanding of its contribution to colonic disorders and
development of therapeutic strategies.
Keywords: sulfur, hydrogen sulfide, colonic microbiota, sulfate-reducing bacteria, inflammatory bowel disease,
colorectal cancer, irritable bowel syndrome
INTRODUCTION
The crucial role of the microbiome in digestive processes and
intestinal health is now fully integrated in gastroenterology
research (Gordon et al., 2007). The immense number of microbes
resident in the small intestine and colon form complex commu-
nities and metabolic interactions, which impact the host ben-
eficially or detrimentally. Accordingly, the intestinal microbiota
plays a central role in digestive biochemistry and element cycling.
Whereas abundant data are available regarding microbial carbon
metabolism (carbohydrate or fiber degradation), less is known
about microbial metabolism of other elements in the human
intestine.
Historically, the sulfur cycle was one of the first to be well doc-
umented in environmental microbiology (Kertesz, 2000; Canfield
and Farquhar, 2012). Chemolithoautotrophic andmetabolic con-
version of sulfur compounds were first described in the late 19th
century by Beijerinck (Kelly et al., 1997) and are of central interest
in the context of environmental pollution (Kellogg et al., 1972).
Many sulfur compounds are also recognized for their toxicity
and impact on human health (Ware et al., 1981). While there is
no evidence for a microbial sulfur cycle per se in digestive sys-
tems, direct and indirect evidence points to a greater diversity and
influence of microbial sulfur metabolism in the human intestine
than previously recognized.
The sulfur present in the human body is provided exclusively
by diet and either converted to sulfated compounds, assimi-
lated by host cells or excreted. Sulfur is generally acquired in
the human diet through protein (Stipanuk, 2004). It is note-
worthy that one essential and another conditionally essential
amino acid (methionine and cysteine, respectively) are sulfated,
and thus, sulfur acquisition is crucial to humans. Cysteine is
considered a conditionally essential amino acid as it can be
synthesized from methionine via transsulfuration (Dominy and
Stipanuk, 2004). As reviewed elsewhere, in addition to dietary
inputs, host sulfur amino acids are actively recycled through a
wide array of metabolic pathways (Stipanuk, 1986, 2004; Stipanuk
and Dominy, 2006). Similar to the host, gut microbes require
sulfur inputs and, because of their active metabolism and tremen-
dous number, are likely to play a major role in the metabolism
of luminal sulfur. Consequently, gut microbes are key players in
determining the balance of beneficial to detrimental effects of
sulfur-containing compounds (Table 1). This review summarizes
microbial pathways influencing sulfur metabolism and their rec-
ognized and potential contributions to colonic health and disease.
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Table 1 | Microbial taxa involved in pathways of colonic sulfur metabolism*.
Sulfur source Sulfur-containing substrate Microbial genus References
Inorganic Sulfate (SO42−) Desulfovibrio spp. (Desulfomonas spp) Gibson et al., 1988; Fite et al., 2004;
Marchesi et al., 2009; Nava et al., 2012
Desulfobacter spp. Gibson et al., 1988; Nava et al., 2012
Desulfobulbus spp. Gibson et al., 1988; Nava et al., 2012
Desulfotomaculum spp. Gibson et al., 1988; Nava et al., 2012
Sulfite (SO32−) Bilophila wadsworthia Baron et al., 1989
Campylobacter jejuni Kelly and Myers, 2005
Organic Cysteine Escherichia coli Metaxas and Delwiche, 1955; Shatalin et al.,
2011
Staphylococcus aureus Shatalin et al., 2011
Salmonella thyphimurium Kredich et al., 1972
Mycobacterium tuberculosis Wheeler et al., 2005
Helicobacter pylori Kim et al., 2006
Leishmania major (protozoa) Nowicki et al., 2010
Prevotella intermedia Igarashi et al., 2009
Fusobacterium nucleatum Yoshida et al., 2010
Streptococcus anginosus Yoshida et al., 2011
Clostridium spp. Genomic cysteine desulfhydrase
Enterobacter spp. Genomic cysteine desulfhydrase
Klebsiella spp. Genomic cysteine desulfhydrase
Desulfovibrio spp. Genomic cysteine desulfhydrase
Sulfomucin Prevotella strain RS2 Roberton et al., 2000
Bacteroides fragilis Roberton et al., 2000
Helicobacter pylori Slomiany et al., 1992
Akkermansia spp. Genomic glycosulfatase
Taurine Bilophila wadsworthia Laue et al., 1997
Sulfated bile acids (rat model) Clostridium perfringens Huijghebaert and Eyssen, 1982;
Huijghebaert et al., 1982; Robben et al., 1986
Estrogen-3-sulfates and phenylsulfates Peptococcus niger Vaneldere et al., 1991
*Assimilatory sulfate reduction, widespread and present in virtually all microbes, has not been included.
INTESTINAL SOURCES OF SULFUR
Food sources of inorganic sulfate include commercial breads,
dried fruits, vegetables, nuts, fermented beverages, and bras-
sica vegetables (Florin et al., 1991). Diets supplemented with
inorganic sulfate stimulate hydrogen sulfide (H2S) production
within the colon (Christl et al., 1992; Lewis and Cochrane, 2007).
Furthermore, in vitro incubation studies using human feces indi-
cate that organic sulfur-containing compounds including cys-
teine, taurocholic acid, andmucin provide a more efficient source
for sulfide production than inorganic sulfate (Florin, 1991; Levine
et al., 1998), with meat being a particularly important source
(Magee et al., 2000). In particular red meat, eggs, and milk con-
tain elevated concentrations of cysteine. Concentrations of both
free cysteine and methionine in colon are relatively low (Ahlman
et al., 1993), indicating efficient metabolism by the microbiota
and host epithelial cells. An additional source of colonic sul-
fur includes the sulfomucins. Mucins, consisting of a peptide
backbone, are largely responsible for the viscous properties of
the colonic mucus layer and can be broadly classified as sialo-
mucins or sulfomucins based on the presence of terminal sialic
acid or sulfate groups, respectively, on the oligosaccharide chain
(Verdugo, 1990; Jass and Roberton, 1994; Croix et al., 2011).
Many other trace sulfated compounds are provided by dietary
elements. In particular, fermented foodstuffs contain a wide array
of volatile sulfur compounds (Landaud et al., 2008). Microbial
and host cell metabolism also produce a large variety of simple
to complex sulfated compounds available for further microbial
utilization or degradation.
MICROBIAL PATHWAYS INVOLVED IN COLONIC SULFUR
METABOLISM
ASSIMILATORY SULFATE REDUCTION
Among microbes, assimilatory sulfate reduction is the most
widespread and essential biochemical process linked to sul-
fur and provides a mechanism by which microorganisms can
reduce sulfate to elemental sulfur in order to satisfy phys-
iological requirements (Peck, 1961). This process is medi-
ated by phosphoadenosine-5′-phosphosulfate (PAPS) reductases
(Figure 1), which are widely distributed among microbes and
other living organisms except animals (for example 2924 hits for
annotated nucleotide sequences and 10,402 for protein sequences
were found in the NCBI database). Assimilatory sulfate reduction
can also be performed by other enzymatic pathways (Vaneldere
et al., 1991; Seitz and Leadbetter, 1995) and likely represents
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FIGURE 1 | Overview of the microbial pathways involved in colonic
sulfur metabolism. The sulfate remaining from assimilatory sulfate
reduction is available for sulfate-reducing bacteria and, thus, H2S
production. Taurine and cysteine are additional potentially important
substrates for microbial production of H2S. Various microbial metabolic
pathways influence the composition and relative abundance of organic
sulfur compounds.
a crucial step in sulfur cycling as it allows for significant dis-
posal of sulfate and conversion to necessary organic sulfated
compounds.
DISSIMILATORY SULFATE REDUCTION
While the process of assimilatory sulfate reduction is widespread
among microbes, only restricted microbial groups are capa-
ble of dissimilatory sulfate reduction (Figure 2). The sulfate-
reducing bacteria (SRB) are notable as the only microbes in
intestinal ecosystems that rely on inorganic sulfate for con-
servation of energy. This sulfate respiration pathway has been
conserved in five bacterial and two archaeal phyla (Wagner
et al., 1998). Most of the SRB belong to the Deltaproteobacteria
with more than 25 genera, followed by the Gram-positive SRB
within the Clostridia (Desulfotomaculum, Desulfosporosinus, and
Desulfosporomusa genera). The SRB use sulfate as a terminal elec-
tron acceptor for respiration, with the concomitant production
of H2S (Peck, 1961). In the colon, sulfate reduction is generally
associated with dihydrogen oxidation (Carbonero et al., 2012),
but the electrons may also be provided from the oxidation of
organic compounds, such as lactate (Flint et al., 2009). SRB
are ubiquitously present in the human intestinal mucosa (Nava
et al., 2012) and have been enumerated by cultivation-dependent
methods from human stool in numbers ranging from 103 to
1011/g (Leclerc et al., 1980; Gibson et al., 1988). In a culture-
based study by Gibson et al., the principal SRB were lactate- and
hydrogen-utilizing Desulfovibrio spp. (64–81%), acetate-utilizing
Desulfobacter spp. (9–16%), propionate- and hydrogen-utilizing
Desulfobulbus spp. (5–8%), lactate-utilizing Desulfomonas spp
(reclassified within the genus Desulfovibrio) (3–10%), and
acetate- and butyrate-utilizing Desulfotomaculum spp. (2%).
However, these observations are based on cultivation meth-
ods, which underestimate true bacterial diversity. More recently
molecular-based techniques have been applied successfully to
FIGURE 2 | Dissimilatory sulfate reduction pathway. Microbial sulfate
reduction relies on sequential catalytic reactions in which reduction of
sulfate is coupled with oxidation of H2 or simple organic molecules. This
anaerobic respiration pathway is less favorable thermodynamically than
aerobic respiration.
describing SRB diversity in various environments. SRB have thus
far been detected and quantified from stool and colonic mucosa
samples (Zinkevich and Beech, 2000; Fite et al., 2004; Nava et al.,
2012). The genusDesulfovibrio has generally been found in higher
numbers (Fite et al., 2004;Marchesi et al., 2009), with lower abun-
dances of Desulfobacter, Desulfobulbus, and Desulfotomaculum
(Nava et al., 2012). The biochemistry of dissimilatory sulfate
reduction has been investigated most extensively within species of
Desulfovibrio. In the environment, SRB are able to utilize a wide
range of substrates as electron donors and acceptors and can even
adopt non-sulfidogenic lifestyles (Plugge et al., 2011). For exam-
ple Desulfobulbus spp. can ferment organic matter under certain
conditions (Kuever et al., 2005). It is not known if colonic SRB
possess the ability to switch from sulfidogenic to non-sulfidogenic
lifestyles in the colon, but an ability to adapt to varying sulfate
levels would confer a competitive advantage.
CYSTEINE DEGRADATION
Cysteine degradation to H2S mediated by L-cysteine desulfhy-
drase (Figure 3) was described in the 1950s in the Escherichia coli
model, a well-known inhabitant of the human gut (Metaxas and
Delwiche, 1955). Since that time, L- or D-cysteine desulfhydrase
have been described in diverse taxa (Kumagai et al., 1975) includ-
ing a few intestinal pathogens such as Salmonella thyphimurium
(Kredich et al., 1972), Mycobacterium tuberculosis (Wheeler et al.,
2005), H. pylori (Kim et al., 2006), and the protozoan Leishmania
major (Nowicki et al., 2010). L- or D-cysteine desulfhydrase have
also been studied in various oral microorganisms as a source of
malodor and abscess formation (Igarashi et al., 2009; Yoshida
et al., 2010, 2011). Those genera found in the oral cavity, namely
Streptococcus, Prevotella and Fusobacterium, are also common
inhabitants of the human colon. A search in the GenBank and EBI
databases revealed that cysteine desulfhydrase-encoding genes
have been annotated in several common colonic genera such
as Clostridium, Enterobacter, Klebsiella, Streptococcus, and, sur-
prisingly, the SRB genus Desulfovibrio. Although desulfhydrase
activity has not been quantified in intestinal ecosystems and
the prevalence of the gene among intestinal taxa remains unde-
fined, it appears likely that desulfhydrase-harboring microbes are
important producers of H2S in the human colon.
Other microbial enzymes possess cysteine desulfhydrase activ-
ity, and, more generally, the ability to convert cysteine or cysteine
analogs is widespread. Cysteine desulfidases, that carry out
reactions similar to other desulfhydrases, have been described in
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FIGURE 3 | Pathways of cysteine degradation to H2S. Cysteine
desulfhydrase is a key enzyme for initial microbial cysteine fermentation
and pyruvate production. However, recent evidence indicates that three
other enzymes orthologous to eukaryotic enzymes may catalyze similar
reactions. The generation of H2S via these four enzymatic pathways may
surpass that by dissimilatory sulfate reduction, especially in hosts
consuming a protein-rich diet.
environmental archaea (Tchong et al., 2005). Beta C-S lyases or
cystathionases mediates the cleavage of cystathionine to homo-
cysteine in E. coli (Zdych et al., 1995) and Lactobacillus spp.
(De Angelis et al., 2002; Irmler et al., 2008). Another example is
the SRB Desulfovibrio desulfuricans, which is able to obtain sul-
fate from cysteine degradation (Forsberg, 1980). Conversely, the
prevalent O-acetyl-L-serine sulfhydrylase (OASS) and homocys-
teine synthase mediate the microbial synthesis of cysteine from
O-acetyl-L-serine and sulfide in bacteria and archaea (Borup and
Ferry, 2000; Tai and Cook, 2001).
A recent paper provided evidence that a high proportion
of bacterial genomes harbor orthologs of mammalian cys-
tathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and
3-mercaptopyruvate sulfurtransferase (3MST), three enzymes
involved in H2S production (Shatalin et al., 2011). The
authors confirmed that pathogenic strains, including E. coli and
Staphylococcus aureus, converted cysteine to H2S through activ-
ities of one of those enzymes. Thus, it may be hypothesized
that many gut microbes are capable of cysteine conversion to
H2S. Further, the authors demonstrated that sulfide produc-
tion reduces oxidative stress, thereby increasing antibiotic resis-
tance potential (Shatalin et al., 2011). Indeed, those microbial
metabolic pathways are very poorly documented in gut commen-
sals, and characterization of these enzymes and associated genes
will be crucial to understanding if microbial-generated sulfide
plays a role in shaping the colonic ecosystem.
TAURINE AND SULFITE RESPIRATION
Only a few genera are able to gain energy through sulfite respi-
ration rather than direct sulfate respiration (Pukall et al., 1999;
Soulimane et al., 2011). Among those, the only intestinal resident
characterized to date is Bilophila wadsworthia, a close relative
of Desulfovibrio spp. (Baron et al., 1989). This unique bacterial
FIGURE 4 | The taurine degradation pathway of Bilophila
wadsworthia. Bilophila wadsworthia is the only known intestinal microbe
that uses taurine as an electron acceptor for anaerobic respiration. The first
two enzymatic reactions result in sulfite production. Sulfite is subsequently
converted to H2S by a dissimilatory sulfite reductase that differs structurally
from those used by sulfate-reducing bacteria.
species has attracted much attention because of its links with var-
ious disease symptoms (Finegold et al., 1992; Arzese et al., 1997;
Aucher et al., 1998; Nakayama et al., 2000; Devkota et al., 2012). It
reduces sulfite after an initial degradation of taurine and harbors
a different dissimilatory sulfite reductase than other SRB (Laue
et al., 2001) (Figure 4). A sulfite oxidation metabolic pathway
has also been demonstrated in the food-borne human pathogen
Campylobacter jejuni (Kelly and Myers, 2005); however, the exis-
tence of similar pathways in intestinal commensal microbes has
not been described.
Taurine, a sulfated compound secreted by the eukaryotic host
that is crucial for chelating bile acids in addition to contributing
to osmoregulation, cardiac function, and retinal development is
degraded by B. wadsworthia using a taurine:pyruvate aminotrans-
ferase to obtain sulfite (Laue et al., 1997; Laue and Cook, 2000)
(Figure 4). An intriguing link between dietary fat and the utiliza-
tion of taurochloric acid as a source of taurine for B. wadsworthia
is suggested by two recent studies (Swann et al., 2011; Devkota
et al., 2012). Compared to mice fed a low fat or high polyun-
saturated fat diet, mice fed a high milk fat diet demonstrated
an overrepresentation of B. wadsworthia, which was determined
to be mediated by taurine-conjugated bile acids (Devkota et al.,
2012). Furthermore, milk fat was essential for colonization by B.
wadsworthia in the germ-free mouse colon. Swann et al. (2011)
demonstrated that the lack of an established microbiota results in
a dominance of taurine-conjugated bile acids over unconjugated
or glycine-conjugated bile acids, suggesting that bile acids, whose
composition is modulated by the gut microbiota, may serve as
signaling molecules in liver and other tissues (Swann et al., 2011).
Although taurine has also been demonstrated to be a substrate
for SRB in marine microbial mats (Visscher et al., 1999), it is not
known if colonic SRB are capable of taurine utilization.
ARYLSULFATASES
Bile acids can be sulfated by the action of host sulfotrans-
ferases, which allow their subsequent detoxification and disposal
(Alnouti, 2009). It was demonstrated in a rat model that the
opposite conversion, bile acid desulfation, can be mediated by
microbial enzymes with arylsulfatase activity (Robben et al.,
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1988). Arylsulfatases were purified from Clostridium perfrin-
gens (Huijghebaert and Eyssen, 1982; Huijghebaert et al., 1982;
Robben et al., 1986) inhabiting the rat intestine and are also
widespread in several abundant colon genera. Little arylsulfatase
activity was reported in human stool (McBain and Macfarlane,
1998), which does not preclude a more extensive activity of
microbial arylsulfatase in the colonic ecosystem where signifi-
cant concentrations of sulfated bile acids are found (Palmer, 1967;
Hofmann et al., 2008).
GLYCOSULFATASES
Some colonic microbes have evolved to degrade colonic mucins
(Roberton and Stanley, 1982; Derrien et al., 2004, 2008). In
particular, microbial glycosulfatases catalyze the release of
sulfate from sulfomucins (Corfield et al., 1992; Roberton and
Wright, 1997). Glycosulfatase enzymes have been described
primarily in the intestinal resident Prevotella strain RS2 and
Bacteroides fragilis (Roberton et al., 2000), but also in the
stomach resident Helicobacter pylori (Slomiany et al., 1992). A
suite of glycosulfatase-like enzymes were also described in the
intestinal Peptococcus niger, using less abundant substrates such
as estrogen-3-sulfates and phenylsulfates (Vaneldere et al., 1991).
Relative abundance and activity of glycosulfatase-harboring
bacteria may greatly influence colonic sulfur metabolism; how-
ever, little is known about prevalence, abundance, and activity
of bacterial glycosulfatases. A search in the GenBank and EBI
databases confirmed that glycosulfatases encoding genes have
been annotated in important colonic genera such as Prevotella,
Bacteroides (Arumugam et al., 2011), and Akkermansia (Belzer
and De Vos, 2012).
LINKS WITH COLONIC HEALTH AND DISEASE
HYDROGEN SULFIDE
Toxicity
Hydrogen sulfide is the most suspect sulfated compound in the
etiology of colonic disorders and inflammation (Nakamura et al.,
2010; Danese and Fava, 2011; Medani et al., 2011). In addition,
it is among the most hazardous gases in industrial applications,
exhibiting toxicity to different organs at low concentrations, with
increasing concentrations being fatal (Guidotti, 1996). There
is ample evidence that H2S at physiological concentrations is
genotoxic and induces DNA damage as well as inflammatory
responses (Attene-Ramos et al., 2006, 2007, 2010). Exogenous
hydrogen sulfide is highly toxic to colonocytes and impairs their
metabolic function, especially butyrate oxidation (Roediger et al.,
1993; Babidge et al., 1998). In the human colon, sulfide exists
largely in the volatile, highly toxic undissociated form (H2S),
which is quickly absorbed by the mucosa or passes as flatus
(Suarez et al., 1997). Over 90% of sulfate disappears during pas-
sage through the colon of individuals lacking a sulfate-reducing
microbiota, indicating that additional colonic processes compete
for sulfate (Strocchi et al., 1993).
Detoxification
Hydrogen sulfide is oxidized in many tissues including colonic
mucosa (Bartholomew et al., 1980; Furne et al., 2001), which
presumably is exposed frequently to bacterial-derived sulfide,
given the persistent colonization of the human colonic mucosa
by SRB (Nava et al., 2012). The first step in the sulfide oxidation
pathway is catalyzed by sulfide quinone reductase (SQR), a
mitochondrial flavoprotein that oxidizes H2S to protein-bound
persulfide. Subsequently, a sulfur dioxygenase and a sulfur
transferase are thought to sequentially convert SQR-bound
persulfide into sulfite and thiosulfate, respectively (Wilson et al.,
2008; Kabil and Banerjee, 2010). Given that most of the colonic
disorders for which a potential pathogenic role for sulfide exists
are effectively gene-environment disorders, it is straight-forward
to envision how common polymorphisms in host genes encoding
components of the sulfide oxidation pathway might underlie
ineffective epithelial sulfide detoxification and thereby predispose
certain individuals to chronic sulfide-generated inflammation or
genotoxicity.
H2S as an endogenous signaling molecule
Despite its potential inflammatory, toxic and genotoxic prop-
erties, there is also evidence that human cells may be able to
use H2S as a inorganic substrate for mitochondrial energiza-
tion (Bouillaud et al., 2007). It is postulated that H2S may be
an important endogenous signaling molecule (Abe and Kimura,
1996; Distrutti et al., 2006). In addition, H2S has been sug-
gested to be an effective drug against various GI diseases in
a rodent model (Wallace et al., 2007, 2009; Wallace, 2010).
However, the potential therapeutic properties of exogenous H2S
still remain controversial (Bouillaud and Blachier, 2011; Olson,
2011). Intriguingly, a recent report demonstrated that inhibi-
tion of H2S synthesis in healthy rats resulted in mucosal injury
and inflammation in the small intestine and colon, while intra-
colonic administration of H2S donors significantly reduced the
severity of trinitrobenzene sulfonic acid-induced colitis (Wallace
et al., 2009). These data indicate that the outright assumption
that colonic H2S is only deleterious may be challenged and jus-
tify additional study of both bacterial and endogenous sources of
H2S in the human colon.
H2S as an architect of microbiome structure
In the context of culture-based microbiology, sulfide in differ-
ent forms has been used as a strong reducing agent, allowing
maintenance of anoxia in media. However, sulfide concentra-
tions must be kept low to avoid toxicity in microbial cells. For
example, in microcosms simulating anaerobic digesters, lactose
fermentation and methanogenesis were inhibited by sulfide in a
dose-dependent manner. Interestingly, it was also observed that
SRB activities were inhibited by increased sulfide concentrations
(Hilton and Oleszkiewicz, 1988). In surface sediments of sandy
intertidal flats, high sulfide concentrations may reduce functional
diversity (Freitag et al., 2003). Finally, sulfide production was
shown to provide cytoprotection from oxidative stress (Shatalin
et al., 2011). As a start, in vitro studies with representative colonic
strains are needed to better understand the potential for sulfide as
well as sulfated compounds to influence the structure of colonic
ecosystem.
INFLAMMATORY BOWEL DISEASE
The two major forms of inflammatory bowel disease (IBD),
Crohn’s disease (CD), and ulcerative colitis (UC), afflict 0.1–0.5%
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of individuals in Western countries (Podolsky, 2002; Hanauer,
2006). It is commonly accepted that IBD results from multi-
factorial interactions among genetic and environmental factors
that lead to a dysregulation of the innate immune response to
the intestinal microbiota in genetically predisposed individuals
(Podolsky, 2002).
Substantial evidence exists for a potential pathogenic role
of H2S in IBD, particularly in UC (Pitcher and Cummings,
1996). Healthy colonic epithelial cells depend on the availabil-
ity of short-chain fatty acids such as butyrate for nutrition.
Butyrate is produced during colonic fermentation and oxidized
by colonocytes via the enzyme acyl-CoA dehydrogenase. Because
this enzyme is inhibited by H2S, oxidation of butyrate is impaired
by H2S (Babidge et al., 1998). Patients with UC were shown to
have reduced breath excretion of CO2 after administration of
butyrate intrarectally, reflecting reduced colonic butyrate oxida-
tion (Den Hond et al., 1998). UC patients with reduced colonic
butyrate oxidation also exhibit increased intestinal permeabil-
ity (Den Hond et al., 1998). Indeed, as ion absorption, mucin
synthesis, membrane lipid synthesis, and detoxification processes
in colonocytes depend on the oxidation of butyrate (Roediger
et al., 1997), decreases of butyrate oxidation would be expected
to compromise epithelial barrier function (Ramakrishna et al.,
1991).
Patients with UC have been shown to consume more pro-
tein and, thereby, more sulfur amino acids than control subjects
(Tragnone et al., 1995). Removing foods such as milk, cheese,
and eggs improved symptoms in UC patients (Truelove, 1961).
Further, the numbers of SRB and rate of sulfidogenesis were
reported greater in UC patients than control cases (Gibson et al.,
1991; Pitcher et al., 2000). In a study comparing patients with
IBD to healthy individuals or patients with other gastrointestinal
symptoms, the prevalence of Desulfovibrio piger detected via PCR
was significantly higher in the IBD patients (Loubinoux et al.,
2002). Levine et al. (1998) found that production of H2S from
feces of patients with UC was 3–4 times greater than from feces
of healthy controls. However, this difference in H2S production
may not have been due to colonization by a greater number of
SRB, as qPCR did not show that patients with active UC harbored
more SRB in stool or rectal mucosa than healthy controls (Fite
et al., 2004). A common treatment regimen for patients with UC
may contribute to conflicting results regarding the density of SRB
populations in UC patients. Specifically, 5-aminosalicylic acid (5-
ASA), an anti-inflammatory medication commonly prescribed
for UC, also inhibits SRB growth and production of H2S (Pitcher
et al., 2000; Edmond et al., 2003). For example, stool sulfide con-
centrations between patients with UC and non-colitic controls
did not differ when the use of salicylates in colitic patients was
not controlled (Moore et al., 1998); in those patients with UC
who were not administered 5-ASA, fecal sulfide concentrations
were significantly greater (Pitcher et al., 2000).
Additional evidence for the role of H2S in UC is the obser-
vation that SRB were found in surgically constructed ileo-anal
pouches of UC patients but not in pouches of patients with famil-
ial adenomatous polyposis (FAP). Furthermore, H2S production
in UC pouches was 10 times greater than that in FAP pouches
(Duffy et al., 2002). Finally, in a later study, the severity of pou-
chitis was positively correlated with fecal concentrations of H2S
(Ohge et al., 2005), possibly reflecting a pathogenic role for this
gas. Coffey et al. (2009) proposed that the surgical creation of
ileo-anal pouches in UC patients might lead to colonic meta-
plasia, which, in turn, could result in increased production of
sulfomucin and, thus, higher colonization by SRB. The adverse
consequences of such colonization would be greater exposure to
potentially proinflammatory concentrations of H2S (Coffey et al.,
2009).
Increased activity of mucin sulfatase, an enzyme belonging
to the glycosulfatase group, was observed in patients with active
UC but not CD (Tsai et al., 1995). In most patients, fluctuations
in fecal sulfatase activity corresponded with severity of clini-
cal disease, suggesting that the increased fecal sulfatase activity
contributed to perpetuation of the disease. In this scenario, indi-
viduals genetically predisposed to a high SRB carriage rate who
then experience increased sulfatase activity might be at increased
risk of UC due to the increased availability of endogenous sul-
fate for SRB sulfide production. Similarly, diets high in exogenous
sources of sulfate would represent the greatest risk for those
genetically predisposed to a higher abundance of SRB.
Recently, a culture-dependent study demonstrated that
mucosal biopsies from IBD patients were more often colonized
by Fusobacterium spp. than those from matched healthy con-
trols (Strauss et al., 2011). It was further demonstrated that
Fusobacterium isolates from IBD patients trigger inflammatory
pathways in colonic cells (Dharmani et al., 2011). Fusobacterium
spp. produce H2S through cysteine desulfhydrase activity. It also
appears possible that direct consumption of cysteine can reduce
in some instances sulfate availability for SRB, thereby possibly
explaining the conflicting reports of SRB association with IBD.
The recent demonstration of selection for B. wadsworthia in the
gut microbiota of mice fed a high-saturated fat diet that was
associated with higher occurrence and severity of colitis com-
pared to those fed high-unsaturated fat (Devkota et al., 2012)
provides a potential mechanistic model for the development of
IBD in susceptible individuals. Notably, this effect was mediated
by an increase of specific bile acids, particularly taurocholic acid,
a potential source of taurine for B. wadsworthia.
COLORECTAL CANCER
Colorectal cancer is the third most frequent cancer worldwide and
the fourth most common cause of cancer death, with respon-
sibility for 4,92,000 deaths annually (Weitz et al., 2005; Ferlay
et al., 2010). Genetic and environmental factors play a signifi-
cant role in the development of colorectal cancer (Kinzler and
Vogelstein, 1996; Rhodes and Campbell, 2002; de la Chapelle,
2004). Although etiologically divided into sporadic (90% of the
cases), hereditary (5–10%), and IBD-associated (2%), all colorec-
tal cancers show multistep development with several mutations
(Kinzler and Vogelstein, 1996; Rhodes and Campbell, 2002; de la
Chapelle, 2004). Doll and Peto (1981) estimated that over 90%
of gastrointestinal cancers are determined by environmental fac-
tors such as diet. It has been suggested that environmental cancer
risk is determined by the interaction between diet and colonic
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microbial metabolism (O’Keefe et al., 2007). Particularly, there is
strong epidemiologic and experimental evidence that diets with
high animal fat and protein (meat) are associated with increased
risk of colorectal cancer (Willett et al., 1990; Sandhu et al., 2001;
Norat et al., 2002). As discussed earlier, meat contains rela-
tively high dietary sulfur, which can promote microbial sulfate
reduction in the colon.
Kanazawa and colleagues (1996) demonstrated that H2S con-
centrations were significantly greater in patients who had pre-
viously undergone surgery for sigmoid colon cancer and who
later developed new epithelial neoplasia of the colon, compared
to individuals of similar age with a healthy colon. The abil-
ity of the colon to detoxify H2S is also reduced in patients
with colon cancer (Ramasamy et al., 2006). The association of
H2S with colon cancer is further supported by the finding that
H2S induces colonic mucosal hyperproliferation, with this effect
reversed by butyrate (Christl et al., 1996). The mucosal hyper-
proliferation effect of H2S may be mediated by mitogen-activated
protein kinase (MAPK)-mediated proliferation (Deplancke and
Gaskins, 2003). Hydrogen sulfide is also a potent genotoxin that
induces direct radical-associated DNA damage (Attene-Ramos
et al., 2006, 2007). Colon cancer in UC and, perhaps, spo-
radic colon cancer in general may reflect genomic instability
resulting from exposure to H2S (Attene-Ramos et al., 2007). As
the number of SRB was reported to be not significantly differ-
ent (Balamurugan et al., 2008) or reduced in colorectal cancer
patients when compared to healthy controls (Scanlan et al., 2009),
impaired detoxification of H2S may be critical to the role of this
compound in colon cancer.
Increased detection of Fusobacterium spp. in CRC tumors has
been reported in two independent studies (Kostic et al., 2011;
Castellarin et al., 2012). As described previously, Fusobacterium
spp. produce H2S through cysteine desulfhydrase activity. As H2S
has been demonstrated to be genotoxic, it can be hypothesized
that it may be one causative metabolite in the etiology of CRC.
It also appears possible that direct bacterial consumption of cys-
teine would limit sulfate availability for SRB, thereby possibly
explaining the conflicting reports of SRB association with CRC.
IRRITABLE BOWEL SYNDROME
Irritable bowel syndrome (IBS) is a functional bowel disor-
der characterized by chronic abdominal pain, bloating, and
abnormal bowel habits (Mayer, 2008). Diarrhea or constipation
may predominate or these symptoms may alternate. Microbial
dysbioses have been described, and as microbial gases excreted in
breath are higher in IBS patients, abnormal microbial pathways
are a possible cause (King et al., 1998).
Consistent with this possibility, it was demonstrated recently
that exogenous H2S (NaHS) inhibits in vitro motor patterns in
the human, rat and mouse colon and jejunum mainly through
an action on multiple potassium channels (Gallego et al., 2008).
Exogenous H2S (NaHS) inhibited nociception induced by col-
orectal distension in both healthy and post-colitic rats (Distrutti
et al., 2006) but, conversely, triggered visceral nociceptive behav-
ior when administered intracolonically in the mouse (Matsunami
et al., 2009). Recently, a functional dysbiosis was described in
constipation-predominant IBS patients with, in particular, a sig-
nificant increase of SRB and fecal sulfide, indicating a potential
role for sulfide in the development of IBS symptoms (Chassard
et al., 2012).
CONCLUSIONS
Microbial sulfur metabolism in the human colon is likely more
extensive than has been previously recognized. For example, H2S,
the sulfated compound with the highest potential influence on
digestive health, can be generated from cysteine degradation as
well as via dissimilatory sulfate reduction. The extent to which
organic sulfur metabolism is operative in the human colon,
how diet influences relative activities of the enzymatic pathways
involved, and which organisms carry out these processes are
poorly understood. In addition, the importance of the microbiota
and the metabolism of sulfated bile acids are now established,
and further work is needed to understand how dietary fat intake
influences these pathways. With clear evidence that the human
colonic mucosa is persistently colonized by SRB, the beneficial
versus toxic effects of H2S need to be delineated. One possibil-
ity is that the mucosal microbiome is shaped in part through
the differential susceptibility of mutualistic microbes to sulfide
toxicity. Clearly, extensive work is needed to understand the pri-
mary pathways for the production of H2S and how their activities
may influence both host andmicrobial components of the colonic
ecosystem. This new body of knowledge may identify relatively
innocuous approaches for the prevention or treatment of chronic
colonic disorders.
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